7-(tetrahydro-2H-pyran-2-yl)-4-(3,4-dimethoxyphenethyl)-2-methyl-2H-pyridazino[4,5-b][1,4]oxazine-3,8(4H,7H)-dione | 652985-94-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 7-(tetrahydro-2H-pyran-2-yl)-4-(3,4-dimethoxyphenethyl)-2-methyl-2H-pyridazino[4,5-b][1,4]oxazine-3,8(4H,7H)-dione
• 英文别名: 4-[2-(3,4-dimethoxyphenyl)ethyl]-2-methyl-7-(oxan-2-yl)pyridazino[4,5-b][1,4]oxazine-3,8-dione
• CAS: 652985-94-9
• 化学式: C₂₂H₂₇N₃O₆
• 分子量: 429.473
• InChiKey: VZZGDOGEPYLNSN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.32
• 重原子数：
  31.0
• 可旋转键数：
  6.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  92.12
• 氢给体数：
  0.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  7-(tetrahydro-2H-pyran-2-yl)-4-(3,4-dimethoxyphenethyl)-2-methyl-2H-pyridazino[4,5-b][1,4]oxazine-3,8(4H,7H)-dione 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以85.6%的产率得到7-(tetrahydro-2H-pyran-2-yl)-4-(3,4-dimethoxyphenethyl)-3-hydroxy-2-methyl-3,4-dihydro-2H-pyridazino[4,5-b][1,4]oxazine-8(7H)-one
  参考文献：
  名称：

  Synthetic Studies on Isoquinoline Derivatives with Multidrug Resistance (MDR) Modulating Activity

  摘要：

  Tetrahydropyridazino-1,4-oxazinoisoquinoline derivatives with multidrug resistance (MDR) modulating activity were designed and synthesized. A key step for cyclization of 1,4-oxazine ring was developed using K2CO3 and CH3CN in one-pot. Among prepared compounds, 2-(4-fluorobenzyl)-9,10-dimethoxy-12-methyl-6,7,11b,12-tetrahydropyridazino[4',5',5,6][1,4]oxazine[3,4,-a]isoquinolin-1(2H)-one (If) exhibited significant MDR reversing activity and low toxicity, which might be as potential MDR agent.

  DOI：

  10.3987/com-03-9918
• 作为产物：
  描述：

  2-氯-N-[2-(3,4-二甲氧基苯基)乙基]丙酰胺 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 生成 7-(tetrahydro-2H-pyran-2-yl)-4-(3,4-dimethoxyphenethyl)-2-methyl-2H-pyridazino[4,5-b][1,4]oxazine-3,8(4H,7H)-dione
  参考文献：
  名称：

  One‐Pot Synthesis of Pyridazino[1,4]oxazin‐3‐ones

  摘要：

  Pyridazino[1,4] oxazin-3-ones were conveniently prepared in a one-pot condensation of N-substituted 2-chloroacetamides with various 5-chloro-pyridazin-6-ones via rearrangement of a spiro-aminoketal intermediate.

  DOI：

  10.1081/scc-120030689